Verum Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
as on 16-06-2024
- Paid Up Capital ₹ 1.00 M
as on 16-06-2024
- Company Age 6 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -6.41%
(FY 2023)
- Profit -10.81%
(FY 2023)
- Ebitda -11.50%
(FY 2023)
- Net Worth -281.79%
(FY 2023)
- Total Assets 42.49%
(FY 2023)
About Verum Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Gouri Paul, Arup Daolagupu, Garima Agarwala, and Four other members serve as directors at the Company.
- CIN/LLPIN
U24304AS2018PTC018491
- Company No.
018491
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Apr 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Shillong
Industry
Company Details
- Location
Silchar, Assam, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Verum Pharmaceuticals?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sujata Choudhury  | Director | 27-Apr-2018 | Current |
| Gouri Paul | Director | 08-Nov-2022 | Current |
| Arup Daolagupu | Director | 23-Sep-2019 | Current |
| Garima Agarwala | Director | 26-Jun-2018 | Current |
| Anjali Dutta | Director | 01-Jun-2018 | Current |
| Arun Sipani | Director | 01-Apr-2021 | Current |
Financial Performance and Corporate Structure Insights of Verum Pharmaceuticals.
Verum Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 6.41% decrease. The company also saw a substantial fall in profitability, with a 10.81% decrease in profit. The company's net worth observed a substantial decline by a decrease of 281.79%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Verum Pharmaceuticals?
In 2023, Verum Pharmaceuticals had a promoter holding of 80.00% and a public holding of 20.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Verum Pharmaceuticals?
Unlock and access historical data on people associated with Verum Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Verum Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Verum Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
